Dimitrios K Christodoulou

Prof. Dimitrios K Christodoulou


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Stergios BoussiosStergios Boussios
Stergios Boussios
MOMehmet Akif Ozturk
Mehmet Akif Ozturk
MMMichele Moschetta
Michele Moschetta
AKAfroditi Karathanasi
Afroditi Karathanasi
NZNikolaos Zakynthinakis-Kyriakou
Nikolaos Zakynthinakis-Kyriakou
NPNicholas Pavlidis
Nicholas Pavlidis
Colorectal cancer (CRC) is the third most common malignancy worldwide. Surgery remains the most important treatment for non-metastatic CRC, and the administration of adjuvant chemotherapy depends mainly on the disease stage, which is still the strongest prognostic factor. A refined understanding of the genomics of CRC has recently been achieved thanks to the widespread use of next generation sequencing with potential future therapeutic implications. Microsatellite instability (MSI) has been suggested as a predictive marker for response to anti-programmed-cell-death protein 1 (PD-1) therapy in solid tumors, including CRC. It should be noted that not all cancers with MSI phenotype respond to anti-PD-1 immunotherapy, highlighting the urgent need for even better predictive biomarkers. Mitogen-Activated Protein Kinase (MAPK) pathway genes KRAS, NRAS, and BRAF represent important molecular targets and could serve as independent prognostic biomarkers in CRC, and identify those who potentially benefit from anti-epidermal growth factor receptor (EGFR) treatment. Emerging evidence has attributed a significant role to inflammatory markers including blood cell ratios in the prognosis and survival of CRC patients; these biomarkers can be easily assessed in routine blood exams and be used to identify high-risk patients or those more likely to benefit from chemotherapy, targeted therapies and potentially immunotherapy. Analysis of cell-free DNA (cfDNA), circulating tumor cells (CTC) and/or micro RNAs (miRNAs) could provide useful information for the early diagnosis of CRC, the identification of minimal residual disease and, the evaluation of the risk of recurrence in early CRC patients. Even the selection of patients suitable for the new targeted therapy is becoming possible with the use of predictive miRNA biomarkers. Finally, the development of treatment resistance with the emergence of chemo-resistance clones after treatment remains the most important challenge in the clinical practice. In this context it is crucial to identify potential biomarkers and therapeutic targets which could lead to development of new and more effective treatments.

27 August 2020 in World Journal of Hepatology
Verified
Journal Article
Open access
SKSofia Kartsoli
Sofia Kartsoli
CKChristina E Kostara
Christina E Kostara
VTVasilis Tsimihodimos
Vasilis Tsimihodimos
EBEleni T Bairaktari
Eleni T Bairaktari
DCDimitrios K Christodoulou
Dimitrios K Christodoulou
Lipidomics in non-alcoholic fatty liver disease

7 June 2018 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
APAlkiviades F. Pappas
Alkiviades F. Pappas
DCDimitrios K Christodoulou
Dimitrios K Christodoulou

1 February 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
NVNikos Viazis
Nikos Viazis
KAkonstantinos argyriou
konstantinos argyriou
Katerina KotzampassiKaterina Kotzampassi
Katerina Kotzampassi
DCDimitrios K Christodoulou
Dimitrios K Christodoulou
PAPeriklis Apostolopoulos
Periklis Apostolopoulos
GMGerassimos J Mantzaris
Gerassimos J Mantzaris
Aim: To establish whether the addition of probiotics to a globally accepted Helicobacter pylori (H. pylori)-eradication scheme may reduce the rates of side effects and increase the eradication rates. Methods. Prospective, randomized, placebo-controlled trial of patients receiving eradication therapy for H. pylori in the eight participating centers. All patients received a 10-day proton pump inhibitor containing non-bismuth quadruple therapeutic regimen for H. pylori eradication (omeprazole 20 mg, amoxycillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg all twice daily orally) and were randomized to receive either probiotics (group A) or placebo (group B). The probiotic used combined four probiotic strains, i.e., Lactobacillus Acidophilus, Lactiplantibacillus plantarum, Bifidobacterium lactis, and Saccharomyces boulardii. Results. Data were analyzed for 329 patients in group A and 335 patients in group B. Fifty six (17.0%) patients in group A and 170 (50.7%) patients in group B reported the occurrence of an H. pylori treatment-associated new symptom or the aggravation of a pre-existing symptom of any severity (p < 0.00001). H. pylori was successfully eradicated in 303 patients in group A (92.0%) and 291 patients in group B (86.8%), (p = 0.028). Conclusion: Adding probiotics to the 10-day concomitant non-bismuth quadruple H. pylori eradication regimen increases the eradication rate and decreases side effects.

1 January 2020 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
FFFotios S. Fousekis
Fotios S. Fousekis
IMIoannis V. Mitselos
Ioannis V. Mitselos
DCDimitrios K Christodoulou
Dimitrios K Christodoulou
Hepatitis E virus (HEV) is a significant health problem with approximately 20 million individuals infected annually. HEV infection has been associated with a wide spectrum of extrahepatic manifestations, including neurological, hematological and renal disorders. Guillain-Barré syndrome and neuralgic amyotrophy are the most frequent neurological manifestations. In addition, HEV infection has been observed with other neurological diseases, such as encephalitis, myelitis and Bell's palsy. Hematologic manifestations include anemia due to glucose-6-phospate dehydrogonase deficiency, autoimmune hemolytic anemia and severe thrombocytopenia. Membranoproliferative glomerulonephritis and relapse IgA nephropathy with or without coexisting cryoglobulinemia appear to be the most common renal injuries related with HEV infection. Also, HEV infection has been associated with acute pancreatitis and other immune-mediated manifestations, such as arthritis and myocarditis. However, the pathophysiologic mechanisms of HEV-related extrahepatic manifestations are still largely unclear.

1 January 2018 in Gastroenterology Research
Verified
Journal Article
Open access
PDF file
FFFotios S. Fousekis
Fotios S. Fousekis
VTVasileios I. Theopistos
Vasileios I. Theopistos
KKKonstantinos H. Katsanos
Konstantinos H. Katsanos
ETEpameinondas V. Tsianos
Epameinondas V. Tsianos
DCDimitrios K Christodoulou
Dimitrios K Christodoulou
Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review